Skip to Content

Press Releases

Date Title Additional Format
Apr 07, 2008
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord|Adams Hepatitis C Conference
CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord|Adams Hepatitis C Conference on Wednesday, April 9, 2008 at 4:00 p.m. EDT.
Apr 07, 2008
Vertex Pharmaceuticals Announces the Date of its First Quarter 2008 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2008 financial results on Monday, April 21, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
Mar 31, 2008
Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on Telaprevir, Investigational HCV Protease Inhibitor, for Presentation at EASL Annual Meeting
CAMBRIDGE, Mass., Mar 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data related to its investigational hepatitis C protease inhibitor telaprevir will be featured in a late-breaker poster presentation during the 43rd Annual Meeting of the
Mar 27, 2008
Vertex Announces Positive Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis
--Interim analysis of 14-day study of VX-770 shows a significant
improvement in lung function --

--Lung function data supported by corresponding improvements in
disease-related biomarkers--

--Results to be shared with health authorities in order to
identify the most rapid path forward --
Mar 14, 2008
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Cowen and Company 28th Annual Health Care Conference
CAMBRIDGE, Mass., Mar 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 8:00 a.m. EDT.
Mar 13, 2008
Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients
- First hepatitis C protease inhibitor to begin Phase 3 clinical development - - Trial designed to confirm potential of telaprevir to increase sustained viral response (SVR) rates with 24-week treatment duration -
Feb 29, 2008
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference
CAMBRIDGE, Mass., Feb 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the Company will participate in an HCV panel, entitled: "HCV: Protease Inhibitors and Beyond" at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in
Feb 19, 2008
Vertex Pharmaceuticals Announces Completion of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5
Feb 13, 2008
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes CAMBRIDGE, Mass., Feb 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that
Feb 12, 2008
Vertex Pharmaceuticals Announces Pricing of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.
Feb 11, 2008
Vertex Pharmaceuticals Reviews 2008 Business Priorities and Reports 2007 Financial Results
-- Focused on first-to-market opportunity with HCV protease
inhibitor telaprevir --

-- Additional drug candidates directed at HCV, cystic fibrosis and
immune-mediated diseases--
Feb 11, 2008
Vertex Pharmaceuticals Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes
CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
Feb 08, 2008
Vertex Pharmaceuticals Announces Webcast of its Presentation at the BIO CEO & Investor Conference 2008
CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008 at 10:15 a.m. EST.
Jan 31, 2008
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
CAMBRIDGE, Mass., Jan 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5, 2008 at 11:40 a.m.
Jan 28, 2008
Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Jan 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2007 financial results on Monday, February 11, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
Jan 23, 2008
Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor
-- Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens -- Vertex plans concurrent second study to support registration -- Final data from both trials anticipated in mid- 2010
Jan 07, 2008
Vertex Pharmaceuticals Reports Progress in Development of Investigational HCV Drug Telaprevir and Provides Business Update
- Formal European scientific advice obtained for telaprevir development program - - Meeting scheduled with FDA for January 2008 on Phase 3 trial design and recent data - - Next-generation HCV protease inhibitor and two investigational compounds for cystic fibrosis in clinical development -
Jan 03, 2008
Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual JPMorgan Healthcare Conference
CAMBRIDGE, Mass., Jan 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008 at 2:00 p.m. PST (5:00 p.m. EST).
Nov 21, 2007
Vertex Pharmaceuticals Announces Webcast of its Presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference
CAMBRIDGE, Mass., Nov 21, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference on Wednesday, November 28, 2007 at 8:45 a.m. EST.
Nov 20, 2007
Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
-- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers -- -- Merck to initiate clinical development of VX-689 --
Displaying 661 - 680 of 825